Pulmonary Embolism Clinical Trials

A listing of Pulmonary Embolism medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 199 clinical trials
A Randomized Trial of Ultrasound-facilitated, Catheter-directed, Thrombolysis Versus Anticoagulation for Acute Intermediate-high Risk Pulmonary Embolism: The Higher-risk Pulmonary Embolism Thrombolysis Study (HI-PEITHO)

There are many available treatments for pulmonary embolism (PE), but the best treatment for this condition is not known. The HI-PEITHO study will compare two treatment options that are both

blood clot
oximetry
angiography
pulmonary angiography
anticoagulation therapy
  • 0 views
  • 10 Oct, 2022
  • 41 locations
The PEERLESS Study (PEERLESS)

embolism (PE), and includes a non-randomized cohort of up to 150 subjects with an absolute contraindication to thrombolytics.

angiography
pulmonary angiography
thrombectomy
troponin
ctpa
  • 5 views
  • 21 Oct, 2022
  • 42 locations
sFlt1/PlGF and Selective Labor Induction to Prevent Preeclampsia at Term (PE37)

Preeclampsia (PE) affects ~5% of pregnancies. Although improved obstetrical care has significantly diminished associated maternal mortality, PE remains a leading cause of maternal

cesarean section
Accepts healthy volunteers
prenatal
  • 0 views
  • 16 May, 2022
  • 12 locations
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

deep venous thrombosis of lower extremity
pulmonary embolism
embolism
clot
deep vein thrombosis
  • 0 views
  • 04 Oct, 2022
  • 12 locations
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (MAGNOLIA)

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

deep venous thrombosis of lower extremity
pulmonary embolism
embolism
clot
dalteparin
  • 0 views
  • 04 Oct, 2022
  • 1 location
Labor Induction in Preeclampsia High-risk Women (FORECAST-IOL)

Preeclampsia (PE) is one of the leading causes of maternal and perinatal morbidity and mortality. This pregnancy-specific disorder poses to both pregnant women and their offspring an increased

perinatal morbidity
  • 0 views
  • 13 Jun, 2022
  • 1 location
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study) (Jason)

/ Pulmonary Embolism (DVT/PE) recurrence.

pulmonary embolism
anticoagulants
diabetes
stroke
anticoagulant therapy
  • 0 views
  • 04 Oct, 2022
  • 1 location
Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis

superficial venous thrombosis (SVT), deep venous thrombosis (DVT), pulmonary embolism (PE)) in patients who have completed the cycle of therapy of the acute phase after superficial vein thrombosis.

  • 9 views
  • 02 Mar, 2022
  • 1 location
LimPrOn: Limburg Pre-eclampsia Investigation (LimPrOn)

Background Multiple adaptations at the cardiovascular system occurs during pregnancy. In the pregnancy condition pre-eclampsia (PE), this adaptations are abnormal

Accepts healthy volunteers
toxemia of pregnancy
eclampsia
hypertension
proteinuria
  • 43 views
  • 03 Mar, 2022
  • 8 locations
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism (HI-PRO)

VTE, defined as the composite of deep vein thrombosis and/or pulmonary embolism at 12 months. Secondary Efficacy Outcome: The composite of death due to cardiovascular cause, nonfatal

embolism
stroke
anticoagulant therapy
apixaban 2.5 mg
infarction
  • 0 views
  • 04 Oct, 2022
  • 1 location